全文获取类型
收费全文 | 3569篇 |
免费 | 177篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 168篇 |
妇产科学 | 67篇 |
基础医学 | 372篇 |
口腔科学 | 122篇 |
临床医学 | 215篇 |
内科学 | 633篇 |
皮肤病学 | 30篇 |
神经病学 | 330篇 |
特种医学 | 75篇 |
外科学 | 529篇 |
综合类 | 82篇 |
预防医学 | 142篇 |
眼科学 | 214篇 |
药学 | 395篇 |
中国医学 | 16篇 |
肿瘤学 | 342篇 |
出版年
2023年 | 30篇 |
2022年 | 94篇 |
2021年 | 149篇 |
2020年 | 74篇 |
2019年 | 96篇 |
2018年 | 141篇 |
2017年 | 60篇 |
2016年 | 103篇 |
2015年 | 114篇 |
2014年 | 147篇 |
2013年 | 179篇 |
2012年 | 323篇 |
2011年 | 328篇 |
2010年 | 168篇 |
2009年 | 145篇 |
2008年 | 227篇 |
2007年 | 209篇 |
2006年 | 188篇 |
2005年 | 160篇 |
2004年 | 139篇 |
2003年 | 90篇 |
2002年 | 96篇 |
2001年 | 55篇 |
2000年 | 45篇 |
1999年 | 33篇 |
1998年 | 24篇 |
1997年 | 14篇 |
1996年 | 13篇 |
1995年 | 19篇 |
1994年 | 11篇 |
1993年 | 8篇 |
1992年 | 13篇 |
1991年 | 14篇 |
1990年 | 15篇 |
1989年 | 17篇 |
1988年 | 17篇 |
1987年 | 23篇 |
1986年 | 17篇 |
1985年 | 18篇 |
1984年 | 8篇 |
1983年 | 8篇 |
1981年 | 7篇 |
1980年 | 10篇 |
1979年 | 14篇 |
1978年 | 11篇 |
1977年 | 9篇 |
1976年 | 8篇 |
1974年 | 9篇 |
1973年 | 11篇 |
1968年 | 13篇 |
排序方式: 共有3762条查询结果,搜索用时 13 毫秒
991.
Weinstock-Guttman B Ramanathan M Lincoff N Napoli SQ Sharma J Feichter J Bakshi R 《Archives of neurology》2006,63(7):957-963
BACKGROUND: Neuromyelitis optica is a severe demyelinating disease that selectively involves the optic nerves and the spinal cord but usually spares the brain. It is considered to have a B-cell-induced pathogenesis. Mitoxantrone hydrochloride, a synthetic anthracenedione approved for worsening relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis, has been shown to primarily suppress the humoral response. OBJECTIVE: To evaluate the benefit of mitoxantrone treatment in patients with relapsing neuromyelitis optica. DESIGN: Prospective 2-year study. SETTING: Academic multiple sclerosis center. PATIENTS: Five patients (3 women and 2 men) with an age range of 20 to 51 years and an Expanded Disability Status Scale score of 2.5 to 6.5 (mean +/- SD, 4.40 +/- 1.88). INTERVENTIONS: Monthly intravenous infusions of mitoxantrone hydrochloride, 12 mg/m2, for 6 months followed by 3 additional treatments every 3 months. MAIN OUTCOME MEASURES: Expanded Disability Status Scale score measured every 3 months and during relapses; findings on orbital, brain, and spinal cord magnetic resonance images performed at baseline and at 3, 6, 12, 18, and 24 months; and visual evoked potentials and results of ophthalmologic evaluations performed at baseline and annually. RESULTS: During the 2 years of treatment, 2 patients each had a relapse once within the initial 5 months of treatment (1 severe and 1 moderate). Improvement was seen clinically and on magnetic resonance images in 4 patients. Patients generally tolerated the treatment well, although 1 patient had a reversible decrease in cardiac ejection fraction. CONCLUSION: Our results suggest a beneficial effect of mitoxantrone treatment for relapsing neuromyelitis optica. 相似文献
992.
Chadha K Weinstock-Guttman B Zivadinov R Bhasi K Muhitch J Feichter J Tamaño-Blanco M Abdelrahman N Ambrus J Munschauer F Ramanathan M 《Archives of neurology》2006,63(11):1579-1584
BACKGROUND: Interferon inhibitory activity (IIA) is a logical candidate for explaining neutralizing antibody-negative partial responsiveness to interferon beta in multiple sclerosis (MS), but its role has not been evaluated. OBJECTIVE: To investigate the role of IIA and soluble interferon-alpha/beta receptor (sIFNR) in determining response of patients with MS to interferon beta therapy. DESIGN: Parallel-group, open-label study. SETTING: Baird Multiple Sclerosis Center, Buffalo, NY. Patients Blood was obtained before and 24 hours after injection of interferon beta-1a from 38 anti-interferon beta neutralizing antibody-negative patients with relapsing-remitting MS and 16 untreated healthy controls. On the basis of clinical parameters of response to interferon beta therapy, the patients were divided into stable or good-responder (n = 20) and active or partial-responder (n = 18) groups. MAIN OUTCOME MEASURES: Quantitative analyses of magnetic resonance imaging were obtained; the IIA and sIFNR levels were measured using bioassay and enzyme-linked immunosorbent assay, respectively. RESULTS: The IIA and sIFNR levels were elevated in MS patients compared with controls (P<.001). The IIA levels were higher in active or partial responders compared with stable or good responders (P<.001); the sIFNR levels were not different between groups. The Extended Disability Status Score and T2 lesion volumes were higher in the active or partial-responder group compared with the stable or good-responder group. Interferon beta-1a did not have short-term effects on the IIA and sIFNR levels. In univariate general linear model and stepwise regression analyses, IIA levels were associated with T2 lesion volume. CONCLUSION: The levels of IIA are associated with increased MS disease activity and with responsiveness to interferon beta therapy in anti-interferon beta neutralizing antibody-negative MS patients. 相似文献
993.
994.
Joel M. Neutel MD ; William H. Bestermann MD ; Eric M. Dyess MD ; Alan Graff MD PA ; Attila Kursun MD ; Santosh Sutradhar PhD ; Carla Yunis MD MPH 《Journal of clinical hypertension (Greenwich, Conn.)》2009,11(1):22-30
Poor control of hypertension or dyslipidemia may at least in part be due to these risk factors being treated in isolation. The Caduet in Untreated Subjects Population (CUSP) trial was an 8-week, randomized, double-blind, placebo-controlled trial evaluating the efficacy/safety of the combination of a calcium channel blocker (amlodipine besylate) and a statin (atorvastatin calcium) in a single-pill form (5/20 mg) plus therapeutic lifestyle changes (TLC) compared with placebo plus TLC in patients with comorbid hypertension and dyslipidemia without evidence of cardiovascular disease. At week 4, additional antihypertensive/lipid-lowering medication was permitted. The primary end point was the proportion of patients in whom the dual goal of blood pressure (<140/90 mm Hg) and low-density lipoprotein cholesterol control (<100 mg/dL) was met at week 4. This dual goal attainment was significantly greater with amlodipine/atorvastatin plus TLC compared with placebo plus TLC at week 4 (47.6% vs 1.7%; P <.001), with further improvements at week 8. Most adverse events were mild to moderate. Therapy with single-pill amlodipine/atorvastatin plus TLC in these patients significantly increased dual blood pressure/low-density lipoprotein cholesterol goal attainment compared with placebo plus TLC. 相似文献
995.
996.
Tohru Takaseya Hideyuki Fumoto Akira Shiose Yoko Arakawa Santosh Rao David J. Horvath Alex L. Massiello Nicole Mielke Ji‐Feng Chen Qun Zhou Raymond Dessoffy Larry Kramer Stephen Benefit Leonard A.R. Golding Kiyotaka Fukamachi 《Artificial organs》2010,34(12):1158-1163
The purpose of this study was to evaluate in vivo the biocompatibility of BioMedFlex (BMF), a new resilient, hard‐carbon, thin‐film coating, as a blood journal bearing material in Cleveland Heart's (Charlotte, NC, USA) continuous‐flow right and left ventricular assist devices (RVADs and LVADs). BMF was applied to RVAD rotating assemblies or both rotating and stator assemblies in three chronic bovine studies. In one case, an LVAD with a BMF‐coated stator was also implanted. Cases 1 and 3 were electively terminated at 18 and 29 days, respectively, with average measured pump flows of 4.9 L/min (RVAD) in Case 1 and 5.7 L/min (RVAD) plus 5.7 L/min (LVAD) in Case 3. Case 2 was terminated prematurely after 9 days because of sepsis. The sepsis, combined with running the pump at minimum speed (2000 rpm), presented a worst‐case biocompatibility challenge. Postexplant evaluation of the blood‐contacting journal bearing surfaces showed no biologic deposition in any of the four pumps. Thrombus inside the RVAD inlet cannula in Case 3 is believed to be the origin of a nonadherent thrombus wrapped around one of the primary impeller blades. In conclusion, we demonstrated that BMF coatings can provide good biocompatibility in the journal bearing for ventricular assist devices. 相似文献
997.
Sandur SK Pandey MK Sung B Ahn KS Murakami A Sethi G Limtrakul P Badmaev V Aggarwal BB 《Carcinogenesis》2007,28(8):1765-1773
998.
Monje ML Ramakrishna NR Young G Drappatz J Doherty LM Wen PY Kesari S 《Journal of neuro-oncology》2007,84(2):179-183
Summary
Background Radiation-induced high-grade gliomas are a rare but serious late complication of radiotherapy. We report a patient with radiation-induced
cerebellar high-grade glioma who had a durable response to temozolomide.
Patients and Methods Case report of a 77-year-old woman with a radiation-induced, high-grade cerebellar glioma that responded durably to temozolomide.
Results Our patient developed a cerebellar high-grade glioma 9 years after treatment for a stage IV (T4N0M0) supraglottic laryngeal
squamous cell carcinoma with cisplatinum and fluorouracil chemotherapy, and subsequently focal head and neck radiotherapy.
Patient was treated with radiation and concurrent temozolomide (only partially due to toxicity) and was stable for 1 year
without further adjuvant treatment. Subsequently the tumor recurred and the patient had a dramatic and durable response to
standard 5 day dosing of adjuvant temozolomide.
Conclusion High-grade gliomas are a late complication of radiation to the central nervous system and may respond to chemotherapy. 相似文献
999.
Westbrook L Manuvakhova M Kern FG Estes NR Ramanathan HN Thottassery JV 《Cancer research》2007,67(23):11393-11401
Cks1, a small protein whose expression is strongly associated with aggressive breast tumors, is a component of cyclin-cdk complexes, as well as the SCF(Skp2) ubiquitin ligase. In these studies, we explored its roles in estrogen receptor-positive breast tumor cells. When exposed to the antiestrogen ICI 182780, these cells accumulate in G(1) by reducing the expression of Cks1, and increasing the levels of p130/Rb2, a cdk2 inhibitor and SCF(Skp2) target. Heregulin beta1 or estradiol abrogate antiestrogen effects by increasing Cks1 expression, down-regulating p130/Rb2 and inducing S phase entry. Depletion of Cks1 in these cells by RNA interference concomitantly decreased Skp2 and up-regulated p130/Rb2 and another SCF(Skp2) target, p27(Kip1). Remarkably, however, Cks1-depleted cells not only exhibit slowed G(1) progression, but also accumulate in G(2)-M due to blocked mitotic entry. Notably, we show that cdk1 expression, which is crucial for M phase entry, is drastically diminished by Cks1 depletion, and that restoration of cdk1 reduces G(2)-M accumulation in Cks1-depleted cells. cdk1 reduction in Cks1-depleted cells is a consequence of a marked decrease in its mRNA and not due to alteration in its proteolytic turnover. Both heregulin beta1 and estradiol could neither restore cdk1 nor sustain cycling in Cks1-depleted cells, although classical estrogen receptor function remained unaltered. Cks1 depletion also decreased Skp2 in human mammary epithelial cells without altering cell cycle progression. Thus, the indispensability of Cks1 to the breast cancer cell cycle, versus its redundancy in normal cells, suggests that Cks1 abrogation could be an effective interventional strategy in breast cancer. 相似文献
1000.
Ishwar Dutt Vats Snehlata Chaudhary Jayashree Karar Mahendra Nath Qadar Pasha Santosh Pasha 《Neuropeptides》2009,43(5):355-362
Endogenous peptide, Met-enkephalin-Arg-Phe (Tyr-Gly-Gly-Phe-Met-Arg-Phe; MERF) induces effects like antinociception, inhibit contraction of guinea pig ileum, mouse vas deferens and anti-tussive action. However, results regarding its functional efficiency and selectivity are controversial. Therefore, present study was undertaken to investigate whether MERF on systemic (intra-peritoneal, i.p.) route of administration induce any antinociception or not; to scrutinize the effect of 6 days chronic i.p. treatment of MERF on expression of μ (MOR1), δ (DOR1) and κ (KOR1) opioid receptors; and finally, the antinociceptive effect of two synthetic peptides, MERFamide and (D-Ala2)-MERFamide was compared with MERF on intracerebroventricular administration in order to understand the role of FMRF moiety in analgesic effect of MERF.Pharmacological results revealed that only 68.4 and 91.2 μmol/kg dose induce significant antinociception among various doses. Further, on 6 days chronic treatment, MERF induced significant antinociception in comparison to saline. Differential expression of MOR1 and KOR1 showed continuous up-regulation throughout the treatment whereas DOR1 showed down-regulation in initial 3 days followed by subsequently up-regulation during the latter observable period. Moreover, variation in opioid receptors expression had not affected the MERF antinociception.In conclusion, present study discursively demonstrates that MERF during chronic treatment interacts with all three opioid receptors (μ, δ and κ) in rats and differently regulates their expression. Further, the interaction was such that the induction was mainly observed at molecular/expression level and not at pharmacological level to affect antinociception. 相似文献